Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Aptamer Group PLC on Monday said it has signed a follow on deal to develop Optimer binders as novel solutions for a direct-to-consumer personal care product.
Aptamer is a York, England-based company which develops custom affinity binders through its proprietary Optimer platform to enable new approaches in therapeutics, diagnostics and research applications.
Optimer binders can function as an antibody alternative.
Aptamer said the deal could be worth up to £185,000, subject to the successful progression of Optimer development.
It added that the contract is an extension following initial positive results from a project with a ‘multi-national consumer goods company’, which it didn’t name.
Last week, Aptamer said it had signed two new contracts with the potential for downstream milestone and licencing payments. The two new fee-for-service contracts are initially worth over £500,000, subject to the successful progression of Optimer development.
Chief Executive Arron Tolley said: ‘It’s been a busy January at Aptamer, and this latest deal reflects the momentum within the business and the demand for our aptamer solutions.
‘We’re pleased to continue our work with this multi-national consumer goods company on this interesting personal care application, further validating our technology and our leadership position in developing novel aptamers. This deal also showcases the wider applicability of our technology and that Optimer binders can support improved solutions within the cosmetic development space.’
Shares in Aptamer were up 3.5% to 41.40 pence each in London on Monday afternoon.
Copyright 2023 Alliance News Ltd. All Rights Reserved.